Alteogen, 3SBio Agree Pact For ‘Biobetter’ Trastuzumab ADC
This article was originally published in PharmAsia News
Executive Summary
Chinese biotech 3SBio has licensed greater China rights to Alteogen’s novel trastuzumab-containing antibody-drug conjugate for breast cancer, in a deal that will expand 3SBio’s biologics pipeline and eventually provide competition in the indication to major firms including Roche.
You may also be interested in...
Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV
Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.
Alteogen Eyes ASEAN, OIC Biosimilar Markets Via Malaysian JV
Alteogen is taking a different strategy versus its bigger South Korean biosimilar rivals as it is aiming to enter the ASEAN and OIC biosimilar markets by establishing a joint venture with a state-owned Malaysian firm.
Should Pharma Be Concerned About Cooling China-Korea Ties?
Despite regional defense policy concerns that have prompted broad moves to limit economic exchanges between China and South Korea, which could also potentially affect ever expanding healthcare collaborations between the two countries, the pharma sector impact so far appears to be limited.